Eliem Therapeutics Analyst Ratings
Eliem Therapeutics Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 02/10/2023 | — | HC Wainwright & Co. | Downgrades | Buy → Neutral | |
| 10/28/2022 | 79.64% | HC Wainwright & Co. | → $6 | Initiates Coverage On | → Buy |
| 08/16/2022 | 19.76% | SVB Leerink | $9 → $4 | Maintains | Outperform |
| 07/11/2022 | 169.46% | SVB Leerink | $13 → $9 | Maintains | Outperform |
| 04/26/2022 | — | Guggenheim | Downgrades | Buy → Neutral | |
| 04/26/2022 | 289.22% | SVB Leerink | $33 → $13 | Maintains | Outperform |
| 09/07/2021 | 858.08% | Guggenheim | → $32 | Initiates Coverage On | → Buy |
| 09/07/2021 | 947.9% | Stifel | → $35 | Initiates Coverage On | → Buy |
| 09/07/2021 | 888.02% | SVB Leerink | → $33 | Initiates Coverage On | → Outperform |
| 日期 | 上行/下行 | 分析公司 | 目标价格变化 | 评级变化 | 上一次/当前评级 |
|---|---|---|---|---|---|
| 02/10/2023 | - | HC Wainwright公司 | 评级下调 | 购买→中性 | |
| 10/28/2022 | 79.64% | HC Wainwright公司 | →$6 | 开始承保 | →购买 |
| 08/16/2022 | 19.76% | SVB Leerink | $9→$4 | 维护 | 跑赢大盘 |
| 07/11/2022 | 169.46% | SVB Leerink | $13→$9 | 维护 | 跑赢大盘 |
| 04/26/2022 | - | 古根海姆 | 评级下调 | 购买→中性 | |
| 04/26/2022 | 289.22% | SVB Leerink | $33→$13 | 维护 | 跑赢大盘 |
| 09/07/2021 | 858.08% | 古根海姆 | →$32 | 开始承保 | →购买 |
| 09/07/2021 | 947.9% | Stifel | →$35 | 开始承保 | →购买 |
| 09/07/2021 | 888.02% | SVB Leerink | →$33 | 开始承保 | →跑赢大盘 |
What is the target price for Eliem Therapeutics (ELYM)?
伊利姆治疗公司(ELYM)的目标价格是多少？
The latest price target for Eliem Therapeutics (NASDAQ: ELYM) was reported by HC Wainwright & Co. on February 10, 2023. The analyst firm set a price target for $0.00 expecting ELYM to fall to within 12 months (a possible -100.00% downside). 6 analyst firms have reported ratings in the last year.
埃利姆治疗公司(纳斯达克：ELYM)的最新目标价是由HC Wainwright&Co.于2023年2月10日报道的。这家分析公司将目标价定为0.00美元，预计ELYM将在12个月内下跌(可能下跌100.00%)。6家分析公司在过去一年公布了评级。
What is the most recent analyst rating for Eliem Therapeutics (ELYM)?
伊利姆治疗公司(ELYM)的最新分析师评级是多少？
The latest analyst rating for Eliem Therapeutics (NASDAQ: ELYM) was provided by HC Wainwright & Co., and Eliem Therapeutics downgraded their neutral rating.
埃利姆治疗公司(纳斯达克代码：ELYM)的最新分析师评级由HC Wainwright&Co.提供，埃利姆治疗公司下调了其中性评级。
When is the next analyst rating going to be posted or updated for Eliem Therapeutics (ELYM)?
Eliem治疗公司(ELYM)的下一次分析师评级将于何时发布或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Eliem Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Eliem Therapeutics was filed on February 10, 2023 so you should expect the next rating to be made available sometime around February 10, 2024.
分析师在进行了广泛的研究后得出股票评级，其中包括查阅公共财务报表，与埃利姆治疗公司的高管和客户交谈，以及听取收益电话会议。大多数分析师每三个月就会这样做一次，所以你每年应该会得到每家公司每家公司的4个评级。Eliem治疗公司的上一次评级是在2023年2月10日提交的，所以你应该预计下一次评级将在2024年2月10日左右的某个时候提供。
Is the Analyst Rating Eliem Therapeutics (ELYM) correct?
分析师对Eliem Treeutics(ELYM)的评级正确吗？
While ratings are subjective and will change, the latest Eliem Therapeutics (ELYM) rating was a downgraded with a price target of $0.00 to $0.00. The current price Eliem Therapeutics (ELYM) is trading at is $3.34, which is out of the analyst's predicted range.
虽然评级是主观的，并将发生变化，但最新的Eliem Treateutics(ELYM)评级被下调，目标价为0.00美元至0.00美元。埃利姆治疗公司(ELYM)目前的交易价格为3.34美元，超出了分析师的预测范围。